The best way to understand what retatrutide can do is to look at the numbers from people who have already taken it. The Phase 2 trial published in the New England Journal of Medicine in 2023 and the Phase 3 TRIUMPH results from December 2025 and May 2026 provide detailed before-and-after data on weight loss, body composition, and metabolic health. This guide translates the clinical trial numbers into real-world terms \u2014 what 28.7% weight loss means for a specific person, how the weight loss happens over time, and what the before-and-after measurements actually look like.<\/p>\n
The most impressive retatrutide before-and-after result comes from the TRIUMPH-1 trial, announced May 21, 2026. Participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks. The high-BMI subgroup \u2014 participants with a BMI of 35 or higher \u2014 lost an average of 30.3% at 104 weeks. The average absolute weight loss was 85.0 pounds in that subgroup.<\/p>\n
To put 30.3% in perspective: a 300-pound person loses 91 pounds and reaches 209 pounds. A 250-pound person loses 76 pounds and reaches 174 pounds. A 200-pound person loses 61 pounds and reaches 139 pounds. These are not marginal improvements \u2014 they represent transitions from Class 2 or 3 obesity to overweight or normal weight categories for many people.<\/p>\n
The TRIUMPH-4 trial, announced December 11, 2025, showed a nearly identical result in a different population: 28.7% average weight loss at 68 weeks, or 71.2 pounds. The consistency across two independent Phase 3 trials with different populations \u2014 one general obesity, one obesity with knee osteoarthritis \u2014 confirms that the results are not a statistical fluke.<\/p>\n
Retatrutide weight loss follows a distinct pattern across the treatment period. In the first 4 weeks, most participants lose 5-10 pounds. This initial loss is primarily water weight and reduced food intake from the GLP-1 appetite suppression effect. The drug has not yet reached therapeutic levels, but the appetite reduction begins immediately.<\/p>\n
Between weeks 4 and 12, as the dose escalates from 2 mg to 4 mg to 6 mg, weight loss accelerates. The Phase 2 data shows an average loss of 10-15% of total body weight by week 12. This is the period when the triple mechanism \u2014 GLP-1 appetite suppression combined with glucagon-mediated energy expenditure \u2014 starts working together. Participants report noticing visible changes in body shape, particularly around the abdomen, during this phase.<\/p>\n
From week 12 to week 48, weight loss continues at a steady rate of approximately 0.5 to 1.5 pounds per week. The rate gradually slows as the initial rapid loss transitions to a more gradual decline. By week 48 in the Phase 2 trial, participants on 12 mg had lost an average of 24.2% of their starting weight. In the longer Phase 3 trials, weight loss continued through week 80 before beginning to plateau.<\/p>\n
The plateau phase \u2014 which appears to begin around week 80 to 104 \u2014 suggests that retatrutide users eventually reach a new metabolic set point where energy intake and expenditure balance. The TRIUMPH-1 data shows that even at 104 weeks, participants maintained their weight loss with no evidence of regain, which distinguishes retatrutide from dietary interventions where regain is the norm after 12 to 18 months.<\/p>\n
Retatrutide trials have not published detailed DEXA body composition data as of May 2026, but the mechanism provides clues about what happens to muscle mass. The glucagon receptor activation promotes lipolysis \u2014 the breakdown of stored fat \u2014 which means a higher proportion of the weight loss should come from fat compared to GLP-1-only drugs. Semaglutide trials showed that approximately 40% of the weight lost on GLP-1 monotherapy comes from lean mass, including muscle. Tirzepatide dual agonism improved that ratio slightly. Retatrutide’s glucagon component should theoretically improve it further by preferentially targeting fat stores for energy.<\/p>\n
Waist circumference measurements from the TRIUMPH-1 trial support improved body composition. Participants showed significant reductions in waist circumference, indicating loss of visceral fat \u2014 the metabolically dangerous fat stored around internal organs. Visceral fat reduction is associated with improved insulin sensitivity, reduced inflammation, and lower cardiovascular risk independent of total weight loss.<\/p>\n
The before-and-after picture for retatrutide extends beyond weight. The TRIUMPH trials measured multiple metabolic health markers. Systolic blood pressure showed improvements consistent with weight loss of the magnitude observed. Glycemic control markers improved even in participants without diabetes. Waist circumference decreased proportionally to total weight loss.<\/p>\n
The TRIUMPH-4 trial added a unique dimension by measuring knee pain in participants with osteoarthritis. Before the trial, participants reported moderate to severe knee pain on standardized pain scales. After 68 weeks of retatrutide, pain scores decreased significantly, likely due to both reduced weight-bearing load and the anti-inflammatory effects of weight loss. This is the kind of before-and-after result that the scale cannot capture but that meaningfully changes quality of life.<\/p>\n
Jake Terry, the 48-year-old Austin resident profiled in Wired, provides a real-world example that mirrors the clinical trial data. Terry started taking grey market retatrutide after struggling with the cost of his daughter’s prescribed semaglutide. He reported losing approximately 25% of his body weight over approximately 10 months \u2014 consistent with the Phase 2 trial average of 24.2% at 48 weeks. His story is not a clinical trial, but it demonstrates that the trial results translate to real-world use with grey market product.<\/p>\n
Terry reported that the weight loss was not linear. He lost rapidly in the first two months, then slowed, then accelerated again after reaching higher doses. His experience highlights an important point: the weekly weight loss is not uniform across the treatment timeline, and expecting steady progress every week sets unrealistic expectations. The trend over months, not weeks, determines the outcome.<\/p>\n
Clinical trial averages do not predict individual results. In every retatrutide trial to date, the range of individual weight loss has been wide. Some participants lost more than 40% of their body weight. Some lost less than 10%. The factors that predict individual response are not yet well understood, though higher starting BMI, female sex, and adherence to the dose schedule have all been associated with better outcomes in post-hoc analyses.<\/p>\n
The critical fact is that retatrutide produced statistically significant weight loss in all completed trials at all doses above 1 mg weekly. The drug works across populations, across doses, and across trial designs. The before-and-after difference is not subtle \u2014 it is the largest weight loss ever demonstrated in a clinical trial of an injectable obesity drug.<\/p>\n
For a detailed breakdown of the complete weight loss data across all trial phases, see our retatrutide weight loss results article<\/a>. For regular updates on trials and research, visit retatrutidebuy.org<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":" The best way to understand what retatrutide can do is to look at the numbers from people who have already taken it. The Phase 2 trial published in the New England Journal of Medicine in 2023 and the Phase 3 TRIUMPH results from December 2025 and May 2026 provide detailed before-and-after data on weight loss, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-40","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/40","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40"}],"version-history":[{"count":0,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/40\/revisions"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}